TG Therapeutics (TGTX) reported a record-setting first quarter for 2026, with U.S. BRIUMVI net product revenue hitting $195 million, exceeding guidance and reflecting a 63% year-over-year growth. The company raised its full-year U.S. revenue guidance to between $885 million and $900 million, bolstered by over 25,000 patients globally now prescribed BRIUMVI. This marks a significant shift from early adoption to a stable, recurring revenue model, as the treatment shows strong patient retention and increasing demand.
The financial implications for TG Therapeutics are substantial, with total revenue for the quarter reaching $205 million. The company is approaching an annualized revenue run rate of nearly $1 billion, driven by consistent commercial growth and a favorable treatment experience. The upcoming Phase III ENHANCE study results and developments in subcutaneous BRIUMVI administration could further expand the addressable market.
Investors should note the strong momentum in patient uptake and revenue growth, which positions TG Therapeutics favorably against competitors in the multiple sclerosis treatment landscape. The ongoing share repurchase program indicates management’s confidence in the stock’s value, reinforcing a bullish outlook for the company’s future performance.
Source: fool.com